Request Trial
upc-image-aug-27
F. JIMENEZ MECA/shutterstock.com
4 April 2023FeaturesAmericasChristopher Sharp, Sarah Taylor, Robert Greene Sterne and Nirav Desai

Why the UPC will be rewarding for US businesses

Patents are presently enforced and challenged in Europe on a country-by-country basis. National decisions may be inconsistent, relief is confined to smaller markets, and—compared with US patent litigation—the potential for large damages awards is limited.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Americas
LSD trade secrets suit over clinical trail info thrown out by judge
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
Americas
Will Mounjaro and Zepbound get their first US generic rival?
30 June 2026   Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026   The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotechnology
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

LSD trade secrets suit over clinical trail info thrown out by judge
Vinson & Elkins grows West Coast patent and trade secrets bench
Will Mounjaro and Zepbound get their first US generic rival?
King & Spalding continues hiring spree from pre-merged Winston
Merck KGaA agrees $11.3bn deal in major life sciences expansion
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Cooley Asia transactions duo make rival firm move